Medovex Corporation (OTCMKTS:MDVX) Short Interest Decreased By 39.69%

February 15, 2018 - By Richard Conner

The stock of Medovex Corporation (OTCMKTS:MDVX) registered a decrease of 39.69% in short interest. MDVX’s total short interest was 177,800 shares in February as published by FINRA. Its down 39.69% from 294,800 shares, reported previously. With 106,600 shares average volume, it will take short sellers 2 days to cover their MDVX’s short positions. The short interest to Medovex Corporation’s float is 1.58%.

The stock decreased 10.42% or $0.05 during the last trading session, reaching $0.43. About 11,571 shares traded. Medovex Corporation (OTCMKTS:MDVX) has risen 3.33% since February 15, 2017 and is uptrending. It has underperformed by 13.37% the S&P500.

MedoveX Corporation, through its subsidiaries, focuses on developing medical devices primarily in the United States and Europe. The company has market cap of $9.08 million. It offers DenerveX device, a disposable single-use kit for the treatment of various medical applications, including pain relief. It currently has negative earnings. The firm serves healthcare providers, physicians, and third-party payors.

More notable recent Medovex Corporation (OTCMKTS:MDVX) news were published by: which released: “News Medovex Corp.MDVX” on February 03, 2015, also with their article: “Medovex Corporation Converts IDE Submission to a Pre-Submission with Food and …” published on December 29, 2017, published: “Medovex Corporation Releases Letter to Shareholders” on November 20, 2017. More interesting news about Medovex Corporation (OTCMKTS:MDVX) were released by: and their article: “Medovex Corporation Presents Initial Data on the DenerveX® System During …” published on February 13, 2018 as well as‘s news article titled: “Medovex Corporation Enters Into International Distribution Agreement With M …” with publication date: September 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: